Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial - The Lancet

Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial - The Lancet

Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial

• David A Palma, MD 
• Robert Olson, MD
• Stephen Harrow, PhD
• Stewart Gaede, PhD
• Alexander V Louie, MD
• Cornelis Haasbeek, MD
• et al.
• Show all authors

Published:April 11, 2019DOI:https://doi.org/10.1016/S0140-6736(18)32487-5